Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
How do we respond to the threat of multidrug-resistant bacteria? Comparison of antibiotic appraisals from 2016 to 2020 of the French, English, and German HTA agencies.
Dumont R, Lengliné E, Delorme C, Bru JP, Ansart S, Aslangul E, Kelley S, Cochat P, Chevret S, Diatta T. Dumont R, et al. Among authors: chevret s. Int J Technol Assess Health Care. 2024 Dec 9;40(1):e72. doi: 10.1017/S0266462324000552. Int J Technol Assess Health Care. 2024. PMID: 39651580 Free PMC article. Review.
Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J, Deniau B, Battistella M, de Masson A, Bensaid B, Jachiet M, Lazaridou I, Bagot M, Bouaziz JD; Saint-Louis CORE (COvid REsearch) group. Delaleu J, et al. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2777-2779.e1. doi: 10.1016/j.jaip.2020.05.046. Epub 2020 Jun 7. J Allergy Clin Immunol Pract. 2020. PMID: 32525093 Free PMC article. No abstract available.
Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.
Rubenstein E, Diemer M, Goldwirt L, Lascoux-Combe C, Chaix ML, Rami A, Ponscarme D, Lafaurie M, Denis B, De Castro N, Gras J, Liegeon G, Sellier PO, Deville L, Chevret S, Delaugerre C, Molina JM. Rubenstein E, et al. Among authors: chevret s. AIDS. 2024 Jul 1;38(8):1267-1269. doi: 10.1097/QAD.0000000000003887. Epub 2024 May 30. AIDS. 2024. PMID: 38814715
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
Molina JM, Gallien S, Chaix ML, El Abbassi EM, Madelaine I, Katlama C, Valin N, Delobel P, Desseaux K, Peytavin G, Saillard J, Raffi F, Chevret S; ANRS 165 Darulight Study Group. Molina JM, et al. Among authors: chevret s. J Antimicrob Chemother. 2018 Aug 1;73(8):2129-2136. doi: 10.1093/jac/dky181. J Antimicrob Chemother. 2018. PMID: 29860402 Clinical Trial.
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V; on the behalf of the FILO group. Tomowiak C, et al. Among authors: chevret s. Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06076-1. Online ahead of print. Ann Hematol. 2024. PMID: 39499299
678 results